Patients with advanced melanoma who have been treated with ipilimumab can survive for up to 10 years, according to the largest analysis of overall survival in patients treated on any globally approved melanoma therapy. In this pooled analysis of long-term survival data, the researchers assessed survival results from 2,985 patients not treated on a clinical trial in addition to data from 1,861 patients treated on various trials. These results confirm the durability of the overall survival trend observed.